Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture

Journal of Bone and Mineral Research

Volumn 18, Issue 8, 2003, Pages 1471-1477

  Miyamoto, Ken Ichi ^a   Suzuki, Hirokazu ^b   Yamamoto, Shinya ^a   Saitoh, Yukie ^a   Ochiai, Eiji ^a   Moritani, Shuzo ^c   Yokogawa, Koichi ^a   Waki, Yoshihiro ^a   Kasugai, Shohei ^d   Sawanishi, Hiroyuki ^b   Yamagami, Hideomi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

^c FUKUI PREFECTURAL UNIVERSITY   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Bone marrow culture; Cyclic AMP; Osteoblastogenesis; Phosphodiesterase 4 inhibitor; Prostaglandin E2

Indexed keywords

11 DEOXYPROSTAGLANDIN E1; 3,4 DIPROPYL 4,5,7,8 TETRAHYDRO 3H IMIDAZO[1,2 I]PURIN 5 ONE; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ALKALINE PHOSPHATASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; INDOMETACIN; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; 3,4 DIPROPYL 4,5,7,8 TETRAHYDRO 3H IMIDAZO(1,2 I)PURIN 5 ONE; 3,4-DIPROPYL-4,5,7,8-TETRAHYDRO-3H-IMIDAZO(1,2-I)PURIN-5-ONE; ANABOLIC AGENT; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PURINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MARROW CULTURE; CONTROLLED STUDY; NONHUMAN; OSSIFICATION; OSTEOBLAST; PROTEIN EXPRESSION; ANIMAL; BONE DEVELOPMENT; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; MALE; METABOLISM; MOUSE; RAT; WISTAR RAT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANABOLIC AGENTS; ANIMALS; BONE MARROW CELLS; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DINOPROSTONE; MALE; MICE; OSTEOBLASTS; OSTEOGENESIS; PHOSPHODIESTERASE INHIBITORS; PURINES; RATS; RATS, WISTAR;

EID: 2142706744     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.8.1471     Document Type: Article

References (31)

1. 2, calcitonin, and 1,25- dihydroxycholecalciferol. Endocrinology 107:1474-1481.
2. Feyen JHM, Wilt G, Moonen P, Bon AD, Nijweide PJ 1984 Stimulation of arachidonic acid metabolism in primary cultures of osteoblast-like cells by hormones and drugs. Prostaglandins 28:769-781.
3. Marusic A, Kalinowski JF, Harrison JR, Centrella M, Raisz LG, Lorenzo JA 1991 Effects of transforming growth factor-beta and IL-1 alpha on prostaglandin synthesis in serum-deprived osteoblastic cells. J Immunol 146:2633-2638.
4. 2 production by interleukin-1α and transforming growth factor a in osteoblastic MC3T3-E1 cells. J Bone Miner Res 9:817-823.
5. 2. Prostaglandins 27:97-103.
6. 2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone 11:253-266.
7. Coleman RA, Smith WL, Narumiya S 1994 Classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205-229.
8. Beavo JA 1995 Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725-748.
9. Conti M, Nemoz G, Sette C, Vicini E 1995 Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocrine Rev 16:370-389.
10. Soderling SH, Bayuga SJ, Beavo JA 1998 Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 95:8991-8996.
11. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB 1998 Isolation and characterization of PDE 9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564.
12. Polson JB, Krzanowski JJ, Szentivanyi A 1982 Inhibition of high affinity cyclic AMP phosphodiesterase and relaxation of canine tracheal smooth muscle. Biochem Pharmacol 31:3404-3406.
13. Miyamoto K, Kurita M, Ohmae S, Sakai R, Sanae F, Takagi K 1994 Selective tracheal relaxation and phosphodiesterase-IV inhibition by xanthine derivatives. Eur J Pharmacol 267:317-322.
14. Semmler J, Wachtel H, Endres S 1993 The specific type IV phosphodiesterase inhibitor rolipram suppress TNFα production by human mononuclear cells. Int J Immunopharmacol 15:409-413.
15. Miyamoto K, Waki Y, Horita T, Kasugai S, Ohya K 1997 Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem Pharmacol 54:613-617.
16. Waki Y, Horita T, Miyamoto K, Ohya K, Kasugai S 1999 Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastogenesis and osteoclastogenesis in culture and its therapeutic effects in rat osteopenia models. Jpn J Pharmacol 79:477-483.
17. Sawanishi H, Suzuki H, Yamamoto S, Waki Y, Kasugai S, Ohya K, Suziki N, Miyamoto K, Takagi K 1997 Selective inhibitors of cyclic AMP-specific phosphodiesterase: Heterocycle-condensed purines. J Med Chem 40:3248-3253.
18. Maniatopoulos C, Sodek J, Melcher AH 1988 Bone formation in vitro by stromal cells obtained from bone marrow of young adult rats. Cell Tissue Res 254:317-330.
19. Kasugai S, Oida S, Iimura T, Arai N, Takeda K, Ohya K, Sasaki S 1995 Expression of prostaglandin E receptor subtypes in bone: Expression of EP2 in bone development. Bone 17:1-4.
20. Kondo H, Ohyama T, Ohya K, Kasugai S 1997 Temporal changes of mRNA expression of matrix proteins and parathyroid hormone and parathyroid hormone-related protein (PTH/PTHrP) receptor in bone development. J Bone Miner Res 12:2089-2097.
21. Waki Y, Miyamoto K, Kasugai S, Ohya K 1995 Osteoporosis-like changes in Walker carcinoma 256-bearing rats, not accompanied with hypercalcemia or parathyroid hormone-related protein production. Jpn J Cancer Res 86:470-476.
22. Labarca C, Paigen K 1980 A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102:344-352.
23. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, Hidaka H 1990 Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase N-[2-(p-bromocinnamylamino)ethyl]-5- isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 265:5267-5272.
24. 2 in growing rats: Metaphyseal hard tissue and cortico-endosteal bone formation. Calcif Tissue Int 37:148-157.
25. 2 in rats. Calcif Tissue Int 52:57-61.
26. Flanagan AM, Chambers TJ 1992 Stimulation of bone nodule formation in vitro by prostaglandin E1 and E2. Endocrinology 130:443-448.
27. Kasugai S 1994 Bone marrow stromal cell culture as a bone formative experimental system: Technical points and applications to bone research. In: Ogura H (ed.) Pharmacological Approach to the Study of the Formation and the Resorption Mechanism of Hard Tissues. Ishiyaku EuroAmerica, Tokyo, Japan, pp. 175-186.
28. Suda M, Tanaka K, Natsui K, Usui T, Tanaka I, Fukushima M, Shigeno C, Konishi J, Narumiya S, Ichikawa A, Nakao K 1996 Prostaglandin E receptor subtypes in mouse osteoblastic cell line. Endocrinology 137:1698-1705.
29. 2 in rat bone marrow cultures is mediated via the EP4 receptor subtype. Am J Physiol 276:E376-E383.
30. 2. Mol Pharmacol 60:36-41.
31. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ 2002 Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109:1405-1415.